MTOR and ovarian carcinoma: Furthermore, a high-throughput proteomic analysis revealed the overexpression of AKT/mTOR pathway molecules and phosphorylated S6 ribosomal protein in small cell lung cancer and ovarian cancer models that exhibit primary resistance to AZD1775 (Li et al. 2020a; Sen et al. 2017).